EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte Studie

A double‐blind pilot study of oral baricitinib in adult patients with lupus erythematosus panniculitis

Jingjing Chen iD, Yijin Luo, Yuanyuan Duan, Liangchun Wang iD, Hai Long, Yi Liu, Xu Yao, Qianjin Lu iD

The Journal of Dermatology · 2024

DOI: 10.1111/1346-8138.17354 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Dermatology, 2024. Verfasst von Jingjing Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy and Rheumatology, Hospital of Dermatology (Institute of Dermatology), Chinese Academy of Medical Sciences and Peking Union Medi…. Hauptthemen laut MEDLINE: Azetidines, Panniculitis, Lupus Erythematosus, Purines, Pyrazoles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 14 Literaturangaben. Gefördert von: Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences, The CAMS Innovation Fund for Medical Sciences (CIFMS), The programs of Hunan Provincial Department of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lupus erythematosus panniculitis (LEP) is a chronic inflammatory skin disease with a significant impact on the overall well‐being of patients. The safety and efficacy of oral baricitinib for the treatment of LEP have not been studied. This study aimed to explore the efficacy of oral baricitinib in patients with LEP who are recalcitrant or intolerant to conventional therapies. Patients (aged ≥18 years) with active LEP (with a revised cutaneous lupus erythematosus disease area and severity index [RCLASI]‐active score ≥4] were randomly assigned 2:1 to baricitinib (4 mg) or placebo (once daily for 20 weeks). The placebo group was switched to baricitinib (4 mg) at week 13, and the final evaluation was conducted at week 24. The primary endpoint was the proportion of patients with an RCLASI‐A score decreased by 20% at week 12. The secondary endpoints included the changes in the Cutaneous Lupus Erythematosus Disease Area and Severity Index active‐(CLASI‐A) score, the Dermatology Life Quality Index (DLQI), the Physician's Global Assessment (PGA) score, and safety. Five patients were enrolled. Three patients received baricitinib (4 mg), and two patients were treated with placebo. Two patients in the baricitinib treatment group showed a significant RCLASI‐A decrease at week 12 and week 24. Two patients in the placebo group had no change in RCLASI‐A at week 12 and a significant decrease at week 24. No new safety events were observed. Treatment with baricitinib was effective and well tolerated in patients with LEP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzetidinesPanniculitis, Lupus ErythematosusPurinesPyrazolesSeverity of Illness IndexSulfonamidesAdultFemaleHumansMaleMiddle AgedAdministration, OralDouble-Blind MethodPilot ProjectsQuality of LifeTreatment Outcome

Stichwörter der Autor:innen

Cutaneous Lupus Erythematosus Disease Area and Severity IndexJanus kinase‐signal transducer and activator of transcriptionRevised Cutaneous Lupus Erythematosus Disease Area and Severity Indexbaricitiniblupus erythematosus panniculitis

Substanzen

AzetidinesbaricitinibPurinesPyrazolesSulfonamides

Autor:innen und Institutionen

  • Department of Allergy and Rheumatology, Hospital of Dermatology (Institute of Dermatology), Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, Jiangsu, China.
  • Department of Dermatology, Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China.
  • Department of Dermatology, The Second Xiangya Hospital of Central South University, Institute of Dermatology and Venereology of Central South University, Hunan Clinical Medicine Research Center for Major Skin Diseases a…
  • Clinical Trials and Cosmetics Testing Center, Hospital for Skin Diseases (Institute of Dermatology), Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, Jiangsu, China.
  • Hospital of Dermatology (Institute of Dermatology), Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, Jiangsu, China.
  • Key Laboratory of Basic and Translational Research on Immune-Mediated Skin Diseases, Chinese Academy of Medical Sciences, Nanjing, Jiangsu, China.

ORCID-Profile: Jingjing Chen, Liangchun Wang, Qianjin Lu

Förderung

  • Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences
  • The CAMS Innovation Fund for Medical Sciences (CIFMS)
  • The programs of Hunan Provincial Department of Science and Technology
  • National Natural Science Foundation of China

Zitieren

APA

Chen, J., Luo, Y., Duan, Y., Wang, L., Long, H., Liu, Y., Yao, X., & Lu, Q. (2024). A double‐blind pilot study of oral baricitinib in adult patients with lupus erythematosus panniculitis. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17354

Vancouver

Chen J, Luo Y, Duan Y, Wang L, Long H, Liu Y, et al. A double‐blind pilot study of oral baricitinib in adult patients with lupus erythematosus panniculitis. The Journal of Dermatology. 2024. doi:10.1111/1346-8138.17354

BibTeX
@article{Chen2024,
  author = {Chen, Jingjing and Luo, Yijin and Duan, Yuanyuan and Wang, Liangchun and Long, Hai and Liu, Yi and Yao, Xu and Lu, Qianjin},
  title = {A double‐blind pilot study of oral baricitinib in adult patients with lupus erythematosus panniculitis},
  journal = {The Journal of Dermatology},
  year = {2024},
  doi = {10.1111/1346-8138.17354}
}
Kostenlos starten →